Biodesix (BDSX) Tax Expense: History & Chart

Biodesix, Inc.(BDSX)

Medical - Diagnostics & Research · Louisville, CO

$29.44+0.38 (+1.31%)

Delayed quote: Oct 6, 2026, 9:39 AM EDT

About Biodesix, Inc.

Biodesix, Inc. is a data-driven diagnostic solutions provider operating across the United States. Its primary focus includes a comprehensive suite of blood-based lung tests, marketed as the Nodify Lung Nodule Risk Assessment (which includes Nodify XL2 and Nodify CDT). These assessments enable clinicians to evaluate the risk of lung cancer in patients with suspicious nodules, aiding in the reclassification of malignancy risk and guiding appropriate treatment pathways. Beyond risk assessment, Biodesix offers additional lung cancer diagnostics such as GeneStrat ddPCR, which detects specific tumor mutations, and VeriStrat, which gauges the patient's immune system status. Both are crucial for establishing prognosis and informing treatment plans. Another offering is the GeneStrat NGS (Next-Generation Sequencing) test, a rapid, blood-based sequencing solution providing results within 72 hours. Through a partnership with Bio-Rad Laboratories, Inc., Biodesix also provides COVID-19 testing services under its Biodesix WorkSafe program, featuring the Bio-Rad SARS-CoV-2 ddPCR test and the Platelia SARS-CoV-2 Total Ab test, an antibody assay for detecting a B-cell immune response indicating recent or prior infection. Furthermore, the company extends its expertise to biopharmaceutical companies, offering diagnostic and clinical research services, alongside clinical trial testing. It also actively discovers, develops, and commercializes companion diagnostics. Originally incorporated as Elston Technologies, Inc. in 2005, Biodesix, Inc. maintains its headquarters in Boulder, Colorado.

Louisville, CO

334 employees

www.biodesix.com

Healthcare / Medical - Diagnostics & Research

Sector: Healthcare
Industry: Medical - Diagnostics & Research
CEO: Scott Hutton

View full financials

Income Tax Expense

The latest quarterly tax expense is $0. Income tax expense is the amount a company pays in federal, state, and foreign income taxes based on its taxable income for the period.

Q2 FY2026 (2026-06-30).

EBT|Net Income|Free Cash Flow|Revenue|Income Statement

Tax Expense

BDSX Tax Expense

$0.00

Reported quarterly tax expense; no daily interpolation. Q2 FY2026 (2026-06-30): $0.00.

Current Tax Expense

Q2 FY2026 · 2026-06-30

QoQ Growth

N/A

Historical Data

Quarters of data available

Quarterly Tax Expense History

Period	Tax Expense	QoQ Growth	YoY Growth
Q2 FY2026Period end 2026-06-30	$0	N/A	N/A
Q1 FY2026Period end 2026-03-31	$0	N/A	N/A
Q4 FY2025Period end 2025-12-31	$0	N/A	N/A
Q3 FY2025Period end 2025-09-30	$0	N/A	N/A
Q2 FY2025Period end 2025-06-30	$0	N/A	N/A
Q1 FY2025Period end 2025-03-31	$0	N/A	N/A
Q4 FY2024Period end 2024-12-31	$0	N/A	N/A
Q3 FY2024Period end 2024-09-30	$0	N/A	N/A
Q2 FY2024Period end 2024-06-30	$0	N/A	N/A
Q1 FY2024Period end 2024-03-31	$0	N/A	N/A
Q4 FY2023Period end 2023-12-31	$0	N/A	N/A
Q3 FY2023Period end 2023-09-30	$0	N/A	N/A
Q2 FY2023Period end 2023-06-30	$0	N/A	N/A
Q1 FY2023Period end 2023-03-31	$0	N/A	N/A
Q4 FY2022Period end 2022-12-31	$0	N/A	N/A
Q3 FY2022Period end 2022-09-30	$0	N/A	N/A
Q2 FY2022Period end 2022-06-30	$0	N/A	N/A
Q1 FY2022Period end 2022-03-31	$0	N/A	N/A
Q4 FY2021Period end 2021-12-31	$0	N/A	N/A
Q3 FY2021Period end 2021-09-30	$0	N/A	N/A
Q2 FY2021Period end 2021-06-30	$0	N/A	N/A
Q1 FY2021Period end 2021-03-31	$0	N/A	N/A
Q4 FY2020Period end 2020-12-31	$0	N/A	N/A
Q3 FY2020Period end 2020-09-30	$0	N/A	N/A
Q2 FY2020Period end 2020-06-30	$0	N/A	N/A
Q1 FY2020Period end 2020-03-31	$0	N/A	N/A
Q4 FY2019Period end 2019-12-31	$0	N/A	N/A
Q3 FY2019Period end 2019-09-30	−$57.00K	N/A	N/A
Q2 FY2019Period end 2019-06-30	$0	N/A	N/A
Q1 FY2019Period end 2019-03-31	$0	N/A	N/A
Q2 FY2018Period end 2018-06-30	$0	N/A	N/A
Q1 FY2018Period end 2018-03-31	$0	N/A	N/A

Growth uses unique fiscal quarters. Missing or ambiguous prior periods render N/A.

Data as of June 30, 2026